Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration (MACULA)

Pfizer

Status: Completed

Conditions: Macular Degeneration; Age-related Macular Degeneration; Neovascular Macular Degeneration

Treatments: Drug: Pegaptanib

Study type: Observational

Funder types: Industry

Identifiers

NCT01245387

A5751021

Details and patient eligibility

About

Long-term observational study to assess the safety, efficacy and quality of life of patients with neovascular age-related macular degeneration (AMD) under Macugen treatment.

Full description

Ophthalmologists who are experienced in doing intravitreal injections in Germany

Enrollment: 1,001 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with neovascular age-related macular degeneration

Exclusion criteria

• none

Trial design

1,001 participants in 1 patient group

Macugen

Treatment:

Drug: Pegaptanib